Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Bausch & Lomb Ophthalmic ZyLET Is “Approvable” At FDA

This article was originally published in The Pink Sheet Daily

  • News
  • Andrew Shelton

Executive Summary

The company expects to launch the anti-inflammatory/antibiotic agent Zylet by year-end. Bausch & Lomb acquired rights to the loteprednol ophthalmic business from Pharmos.

You may also be interested in...



Bausch & Lomb ZyLET Clears FDA

Loteprednol/tobramycin ophthalmic will be marketed by sales force that had been promoting the conjunctivitis agent Optivar.

Bausch & Lomb ZyLET Clears FDA

Loteprednol/tobramycin ophthalmic will be marketed by sales force that had been promoting the conjunctivitis agent Optivar.

B&L Will Shift Optivar Reps To Anticipated New Product Launches In 2005

Reps will support projected launches for ZyLET and Retisert following the end of a co-promotion agreement for MedPointe's Optivar. B&L expects action on the ZyLET NDA next year and on the Retisert application by year-end.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works

ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages

Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug

See All
UsernamePublicRestriction

Register

PS060493

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By